Patient and donor characteristics and details of procedures
. | Donor without KIR ligand incompatibility . | . | Donor with KIR ligand incompatibility . | |
|---|---|---|---|---|
. | HLA fully matched . | HLA mismatched, without KIR ligand disparity . | HLA mismatched, with KIR ligand disparity . | |
| N | 61 | 49 | 20 | |
| Median patient age, y (range) | 20 (0.5-40) | 18 (0.5-40) | 20.5 (0.5-40) | |
| Median donor age, y (range) | 36 (19.5-53) | 34 (19-56) | 33 (20-54) | |
| Patient/donor sex | ||||
| M/M, n (%) | 23 (38) | 24 (49) | 9 (45) | |
| M/F, n (%) | 11 (18) | 5 (10) | 4 (20) | |
| F/M, n (%) | 9 (15) | 7 (14) | 4 (20) | |
| F/F, n (%) | 18 (30) | 13 (27) | 3 (15) | |
| Patient/donor CMV status* | ||||
| Positive/positive, n (%) | 19 (31) | 22 (45) | 5 (25) | |
| Positive/negative, n (%) | 27 (44) | 17 (35) | 10 (50) | |
| Negative/positive, n (%) | 7 (11) | 4 (8) | 3 (15) | |
| Negative/negative, n (%) | 8 (13) | 6 (12) | 2 (10) | |
| Diagnosis | ||||
| ALL, n (%) | 19 (31) | 13 (27) | 6 (30) | |
| CR1, n | 3 | 5 | 1 | |
| CR2, n | 12 | 6 | 3 | |
| CR3, n | 1 | 1 | 1 | |
| Relapse, n | 3 | 3 | 1 | |
| AML, n (%) | 11 (18) | 6 (12) | 5 (30) | |
| CR1, n | 4 | 2 | 2 | |
| CR2, n | 5 | 2 | 3 | |
| Primary resistance, n | 1 | 0 | 0 | |
| Relapse, n | 1 | 2 | 0 | |
| MDS, n (%) | 9 (15) | 12 (24) | 2 (10) | |
| CR1, n | 2 | 1 | 0 | |
| Nonremission, n | 7 | 11 | 2 | |
| CML, n (%) | 19 (31) | 17 (35) | 6 (30) | |
| Chronic phase 1, n | 19 | 20 | 5 | |
| Blast crisis, n | 0 | 0 | 1 | |
| NHL, n (%) | 1 (2) | 1 (2) | 0 (0) | |
| CR2, n | 1 | 1 | 0 | |
| HD, n (%) | 0 (0) | 0 (0) | 1 (5) | |
| Relapse, n | 0 | 0 | 1 | |
| MM, n (%) | 2 (3) | 0 (0) | 0 (0) | |
| Primary resistance, n | 1 | 0 | 0 | |
| Relapse, n | 1 | 0 | 0 | |
| Disease phase at HSC transplantation† | ||||
| Early, n (%) | 46 (75) | 32 (65) | 14 (70) | |
| Advanced, n (%) | 15 (25) | 17 (35) | 6 (30) | |
| Patient/donor HLA compatibility | ||||
| Single mismatch, n (%) | 0 | 35 (71) | 12 (60) | |
| Multiple mismatch, n (%) | 0 | 14 (29) | 8 (40) | |
| Source of stem cells | ||||
| BM, n (%) | 59 (97) | 48 (98) | 18 (90) | |
| PB, n (%) | 2 (3) | 1 (2) | 2 (10) | |
| Preparative regimen | ||||
| TBI-based, n (%) | 29 (48) | 23 (47) | 11 (55) | |
| Busulfan-based, n (%) | 32 (52) | 26 (53) | 9 (45) | |
. | Donor without KIR ligand incompatibility . | . | Donor with KIR ligand incompatibility . | |
|---|---|---|---|---|
. | HLA fully matched . | HLA mismatched, without KIR ligand disparity . | HLA mismatched, with KIR ligand disparity . | |
| N | 61 | 49 | 20 | |
| Median patient age, y (range) | 20 (0.5-40) | 18 (0.5-40) | 20.5 (0.5-40) | |
| Median donor age, y (range) | 36 (19.5-53) | 34 (19-56) | 33 (20-54) | |
| Patient/donor sex | ||||
| M/M, n (%) | 23 (38) | 24 (49) | 9 (45) | |
| M/F, n (%) | 11 (18) | 5 (10) | 4 (20) | |
| F/M, n (%) | 9 (15) | 7 (14) | 4 (20) | |
| F/F, n (%) | 18 (30) | 13 (27) | 3 (15) | |
| Patient/donor CMV status* | ||||
| Positive/positive, n (%) | 19 (31) | 22 (45) | 5 (25) | |
| Positive/negative, n (%) | 27 (44) | 17 (35) | 10 (50) | |
| Negative/positive, n (%) | 7 (11) | 4 (8) | 3 (15) | |
| Negative/negative, n (%) | 8 (13) | 6 (12) | 2 (10) | |
| Diagnosis | ||||
| ALL, n (%) | 19 (31) | 13 (27) | 6 (30) | |
| CR1, n | 3 | 5 | 1 | |
| CR2, n | 12 | 6 | 3 | |
| CR3, n | 1 | 1 | 1 | |
| Relapse, n | 3 | 3 | 1 | |
| AML, n (%) | 11 (18) | 6 (12) | 5 (30) | |
| CR1, n | 4 | 2 | 2 | |
| CR2, n | 5 | 2 | 3 | |
| Primary resistance, n | 1 | 0 | 0 | |
| Relapse, n | 1 | 2 | 0 | |
| MDS, n (%) | 9 (15) | 12 (24) | 2 (10) | |
| CR1, n | 2 | 1 | 0 | |
| Nonremission, n | 7 | 11 | 2 | |
| CML, n (%) | 19 (31) | 17 (35) | 6 (30) | |
| Chronic phase 1, n | 19 | 20 | 5 | |
| Blast crisis, n | 0 | 0 | 1 | |
| NHL, n (%) | 1 (2) | 1 (2) | 0 (0) | |
| CR2, n | 1 | 1 | 0 | |
| HD, n (%) | 0 (0) | 0 (0) | 1 (5) | |
| Relapse, n | 0 | 0 | 1 | |
| MM, n (%) | 2 (3) | 0 (0) | 0 (0) | |
| Primary resistance, n | 1 | 0 | 0 | |
| Relapse, n | 1 | 0 | 0 | |
| Disease phase at HSC transplantation† | ||||
| Early, n (%) | 46 (75) | 32 (65) | 14 (70) | |
| Advanced, n (%) | 15 (25) | 17 (35) | 6 (30) | |
| Patient/donor HLA compatibility | ||||
| Single mismatch, n (%) | 0 | 35 (71) | 12 (60) | |
| Multiple mismatch, n (%) | 0 | 14 (29) | 8 (40) | |
| Source of stem cells | ||||
| BM, n (%) | 59 (97) | 48 (98) | 18 (90) | |
| PB, n (%) | 2 (3) | 1 (2) | 2 (10) | |
| Preparative regimen | ||||
| TBI-based, n (%) | 29 (48) | 23 (47) | 11 (55) | |
| Busulfan-based, n (%) | 32 (52) | 26 (53) | 9 (45) | |
All differences among the 3 groups were not statistically significant (P > .1). M indicates male; F, female; CMV, cytomegalovirus; CR, complete remission; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation
CMV status was tested by serologic methods
Patients with ALL or AML in CR1 and CR2 or CML-first chronic phase or with low-blast MDS were considered in early disease phase